We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals
ATNM

44 hedge funds and large institutions have $5.78M invested in Actinium Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

36% more capital invested

Capital invested by funds: $4.24M → $5.78M (+$1.54M)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2% more funds holding

Funds holding: 43 → 44 (+1)

0.23% more ownership

Funds ownership: 0.25% → 0.48% (+0.23%)

Holders
44
Holders Change
+1
Holders Change %
+2.33%
% of All Funds
0.96%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
10
Reduced
6
Closed
5
Calls
$42K
Puts
–
Net Calls
+$42K
Net Calls Change
-$36K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$2.79M
2
SCM
Sio Capital Management
New York
+$1.54M
3
ECM
Endurant Capital Management
California
+$831K
4
FI
Fosun International
China
+$181K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$52.2K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$513K
2
DAM
DLD Asset Management
New York
-$68K
3
Deutsche Bank
Deutsche Bank
Germany
-$28K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$23K
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$20K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Bridgeway Capital Management
Texas
$8K – – –
SXL
27
Summit X LLC
Missouri
$8K – – –
VFA
28
Valeo Financial Advisors
Indiana
$8K – – –
MCC
29
Malaga Cove Capital
California
$7K – – –
Squarepoint
30
Squarepoint
New York
$6K -$804 -80 -10%
DY
31
Dowling & Yahnke
California
$6K – – –
TSS
32
Two Sigma Securities
New York
$6K +$3.95K +393 +81%
HFM
33
Hartford Financial Management
Connecticut
$4K – – –
RJA
34
Raymond James & Associates
Florida
$4K – – –
RJFSA
35
Raymond James Financial Services Advisors
Florida
$4K – – –
Millennium Management
36
Millennium Management
New York
$4K +$5.11K +509 New
Morgan Stanley
37
Morgan Stanley
New York
$3K -$342 -34 -7%
TC
38
Truvestments Capital
Florida
$3K – – –
BEAM
39
Baker Ellis Asset Management
Washington
$2K – – –
WS
40
Wedbush Securities
California
$2K – – –
FAM
41
Formidable Asset Management
Ohio
$2K +$3.35K +333 New
Northwestern Mutual Wealth Management
42
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
Bank of America
43
Bank of America
North Carolina
$1K +$774 +77 +241%
DAM
44
DLD Asset Management
New York
– -$68K -4,689 Closed
Deutsche Bank
45
Deutsche Bank
Germany
– -$28K -1,983 Closed
Bank of New York Mellon
46
Bank of New York Mellon
New York
– -$23K -1,565 Closed
Hudson Bay Capital Management
47
Hudson Bay Capital Management
Connecticut
– -$20K -1,410 Closed
William Blair & Company
48
William Blair & Company
Illinois
– -$8K -567 Closed
TCOV
49
Trust Company of Vermont
Vermont
– +$502 +50 New
1
2

ATNM Hedge Fund Activity: Q2 2019 in Review

44 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2019, worth a combined $5.78M — up 36% from $4.24M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ATNM positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 6 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $2.79M. The largest seller was Vanguard Group, cutting an estimated $513K.

  • 44 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2019, up from 43 in Q1 2019.
  • Funds reported $5.78M of Actinium Pharmaceuticals stock for Q2 2019, up 36% quarter-over-quarter.
  • 6 funds opened new Actinium Pharmaceuticals positions in Q2 2019 and 5 closed out, a net change of +1 holder.
  • The largest Actinium Pharmaceuticals buyer in Q2 2019 was Sabby Management, an estimated $2.79M added.
  • The largest Actinium Pharmaceuticals seller in Q2 2019 was Vanguard Group, an estimated $513K sold.

Based on aggregated 13F filings for Q2 2019.